Remoxipride (BioDeep_00000614950)

   


代谢物信息卡片


Remoxiprida [INN-Spanish];Remoxipride [Usan:Ban:Inn];Remoxipridum [INN-Latin];Romoxipride

化学式: C16H23BrN2O3 (370.0891948)
中文名称: 瑞莫必利
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CCN1CCCC1CNC(=O)C2=C(C=CC(=C2OC)Br)OC
InChI: InChI=1S/C16H23BrN2O3/c1-4-19-9-5-6-11(19)10-18-16(20)14-13(21-2)8-7-12(17)15(14)22-3/h7-8,11H,4-6,9-10H2,1-3H3,(H,18,20)/t11-/m0/s1

描述信息

D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents
D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents
D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants
N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AL - Benzamides
C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist

同义名列表

3 个代谢物同义名

Remoxipride; Remoxiprida [INN-Spanish];Remoxipride [Usan:Ban:Inn];Remoxipridum [INN-Latin];Romoxipride; 3-bromo-N-{[(2S)-1-ethylpyrrolidin-2-yl]methyl}-2,6-dimethoxybenzamide



数据库引用编号

8 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Amit Taneja, An Vermeulen, Dymphy R H Huntjens, Meindert Danhof, Elizabeth C M De Lange, Johannes H Proost. Modeling of prolactin response following dopamine D2 receptor antagonists in rats: can it be translated to clinical dosing?. Pharmacology research & perspectives. 2017 12; 5(6):. doi: 10.1002/prp2.364. [PMID: 29226628]
  • W J van den Brink, J Elassaiss-Schaap, B Gonzalez-Amoros, A C Harms, P H van der Graaf, T Hankemeier, E C M de Lange. Multivariate pharmacokinetic/pharmacodynamic (PKPD) analysis with metabolomics shows multiple effects of remoxipride in rats. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2017 Nov; 109(?):431-440. doi: 10.1016/j.ejps.2017.08.031. [PMID: 28882765]
  • Willem J van den Brink, Yin C Wong, Berfin Gülave, Piet H van der Graaf, Elizatbeth C M de Lange. Revealing the Neuroendocrine Response After Remoxipride Treatment Using Multi-Biomarker Discovery and Quantifying It by PK/PD Modeling. The AAPS journal. 2017 01; 19(1):274-285. doi: 10.1208/s12248-016-0002-3. [PMID: 27785749]
  • Daniel J Warner, Hongming Chen, Louis-David Cantin, J Gerry Kenna, Simone Stahl, Clare L Walker, Tobias Noeske. Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug metabolism and disposition: the biological fate of chemicals. 2012 Dec; 40(12):2332-41. doi: 10.1124/dmd.112.047068. [PMID: 22961681]
  • Jasper Stevens, Bart A Ploeger, Margareta Hammarlund-Udenaes, Gunilla Osswald, Piet H van der Graaf, Meindert Danhof, Elizabeth C M de Lange. Mechanism-based PK-PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans. Journal of pharmacokinetics and pharmacodynamics. 2012 Oct; 39(5):463-77. doi: 10.1007/s10928-012-9262-4. [PMID: 22791078]
  • Jasper Stevens, Bart A Ploeger, Piet H van der Graaf, Meindert Danhof, Elizabeth C M de Lange. Systemic and direct nose-to-brain transport pharmacokinetic model for remoxipride after intravenous and intranasal administration. Drug metabolism and disposition: the biological fate of chemicals. 2011 Dec; 39(12):2275-82. doi: 10.1124/dmd.111.040782. [PMID: 21903866]
  • Jasper Stevens, Dirk-Jan van den Berg, Sanne de Ridder, Harm A G Niederländer, Piet Hein van der Graaf, Meindert Danhof, Elizabeth C M de Lange. Online solid phase extraction with liquid chromatography-tandem mass spectrometry to analyze remoxipride in small plasma-, brain homogenate-, and brain microdialysate samples. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2010 Apr; 878(13-14):969-75. doi: 10.1016/j.jchromb.2010.02.024. [PMID: 20303836]
  • Eva Choong, Serge Rudaz, Astrid Kottelat, Davy Guillarme, Jean-Luc Veuthey, Chin B Eap. Therapeutic drug monitoring of seven psychotropic drugs and four metabolites in human plasma by HPLC-MS. Journal of pharmaceutical and biomedical analysis. 2009 Dec; 50(5):1000-8. doi: 10.1016/j.jpba.2009.07.007. [PMID: 19683888]
  • Manthena V S Varma, Bo Feng, R Scott Obach, Matthew D Troutman, Jonathan Chupka, Howard R Miller, Ayman El-Kattan. Physicochemical determinants of human renal clearance. Journal of medicinal chemistry. 2009 Aug; 52(15):4844-52. doi: 10.1021/jm900403j. [PMID: 19445515]
  • Mehran Salehpour, Niklas Forsgard, Göran Possnert. FemtoMolar measurements using accelerator mass spectrometry. Rapid communications in mass spectrometry : RCM. 2009 Mar; 23(5):557-63. doi: 10.1002/rcm.3903. [PMID: 19177507]
  • R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals. 2008 Jul; 36(7):1385-405. doi: 10.1124/dmd.108.020479. [PMID: 18426954]
  • Erik Johnsen, Hugo A Jørgensen. Effectiveness of second generation antipsychotics: a systematic review of randomized trials. BMC psychiatry. 2008 Apr; 8(?):31. doi: 10.1186/1471-244x-8-31. [PMID: 18439263]
  • Stéphane Bastianetto, Marc Danik, Françoise Mennicken, Sylvain Williams, Rémi Quirion. Prototypical antipsychotic drugs protect hippocampal neuronal cultures against cell death induced by growth medium deprivation. BMC neuroscience. 2006 Mar; 7(?):28. doi: 10.1186/1471-2202-7-28. [PMID: 16573831]
  • John C L Erve, Mats A Svensson, Hans von Euler-Chelpin, Eva Klasson-Wehler. Characterization of glutathione conjugates of the remoxipride hydroquinone metabolite NCQ-344 formed in vitro and detection following oxidation by human neutrophils. Chemical research in toxicology. 2004 Apr; 17(4):564-71. doi: 10.1021/tx034238n. [PMID: 15089099]
  • Franco Lombardo, R Scott Obach, Marina Y Shalaeva, Feng Gao. Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. Journal of medicinal chemistry. 2004 Feb; 47(5):1242-50. doi: 10.1021/jm030408h. [PMID: 14971904]
  • Philip Seeman. Atypical antipsychotics: mechanism of action. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2002 Feb; 47(1):27-38. doi: . [PMID: 11873706]
  • L B Nilsson. High sensitivity determination of the remoxipride hydroquinone metabolite NCQ-344 in plasma by coupled column reversed-phase liquid chromatography and electrochemical detection. Biomedical chromatography : BMC. 1998 Mar; 12(2):65-8. doi: 10.1002/(sici)1099-0801(199803/04)12:2<65::aid-bmc722>3.0.co;2-f. [PMID: 9568272]
  • M E DePuy, J L Demetriades, D G Musson, J D Rogers. Stereoselective determination of R-(+)- and S-(-)-remoxipride, a dopamine D2-receptor antagonist, in human plasma by chiral high-performance liquid chromatography. Journal of chromatography. B, Biomedical sciences and applications. 1997 Oct; 700(1-2):165-73. doi: 10.1016/s0378-4347(97)00243-0. [PMID: 9390726]
  • K L Liu, F W Lung. [Difference in prolaction response of schizophrenic patients to equivalent doses of haloperidol, remoxipride and sulpiride]. The Kaohsiung journal of medical sciences. 1996 Dec; 12(12):685-90. doi: NULL. [PMID: 9011126]
  • D C Main, A E Waterman, I C Kilpatrick. Disposition of remoxipride in plasma and cerebrospinal fluid in sheep. Journal of veterinary pharmacology and therapeutics. 1996 Oct; 19(5):402-4. doi: 10.1111/j.1365-2885.1996.tb00071.x. [PMID: 8905576]
  • G Movin-Osswald, M Hammarlund-Udenaes. Prolactin release after remoxipride by an integrated pharmacokinetic-pharmacodynamic model with intra- and interindividual aspects. The Journal of pharmacology and experimental therapeutics. 1995 Aug; 274(2):921-7. doi: NULL. [PMID: 7636755]
  • G Movin-Osswald, M Hammarlund-Udenaes, C Von Bahr, P Eneroth, K Walton-Bowen. Influence of the dosing interval on prolactin release after remoxipride. British journal of clinical pharmacology. 1995 May; 39(5):503-10. doi: 10.1111/j.1365-2125.1995.tb04487.x. [PMID: 7669486]
  • E Mrtensson, G Nyberg. [A study of remoxipride dosage and plasma concentration. New psychopharmaceuticals should be followed-up more strictly]. Lakartidningen. 1994 Aug; 91(34):2948-9. doi: NULL. [PMID: 7990536]
  • G Movin-Osswald, J Boelaert, M Hammarlund-Udenaes, L B Nilsson. The pharmacokinetics of remoxipride and metabolites in patients with various degrees of renal function. British journal of clinical pharmacology. 1993 Jun; 35(6):615-22. doi: 10.1111/j.1365-2125.1993.tb04191.x. [PMID: 8329289]
  • M Aravagiri, S R Marder, T Van Putten, K K Midha. Determination of risperidone in plasma by high-performance liquid chromatography with electrochemical detection: application to therapeutic drug monitoring in schizophrenic patients. Journal of pharmaceutical sciences. 1993 May; 82(5):447-9. doi: 10.1002/jps.2600820503. [PMID: 7689651]
  • M Widman, L B Nilsson, B Bryske, J Lundström. Disposition of remoxipride in different species. Species differences in metabolism. Arzneimittel-Forschung. 1993 Mar; 43(3):287-97. doi: NULL. [PMID: 8489555]
  • H Vartiainen, E Leinonen, A Putkonen, S Lang, U Hagert, U Tolvanen. A long-term study of remoxipride in chronic schizophrenic patients. Acta psychiatrica Scandinavica. 1993 Feb; 87(2):114-7. doi: 10.1111/j.1600-0447.1993.tb03340.x. [PMID: 8447237]
  • W Yisak, L Farde, C von Bahr, L B Nilsson, G Fredriksson, S Ogenstad. Interaction study between remoxipride and biperiden. Psychopharmacology. 1993; 111(1):27-32. doi: 10.1007/bf02257403. [PMID: 7870930]
  • S O Ogren, J Lundström, L B Nilsson. Concentrations of remoxipride and its phenolic metabolites in rat brain and plasma. Relationship to extrapyramidal side effects and atypical antipsychotic profile. Journal of neural transmission. General section. 1993; 94(3):199-216. doi: 10.1007/bf01277025. [PMID: 8123230]
  • S O Ogren, J Lundström, L B Nilsson, M Widman. Dopamine D2 blocking activity and plasma concentrations of remoxipride and its main metabolites in the rat. Journal of neural transmission. General section. 1993; 93(3):187-203. doi: 10.1007/bf01244996. [PMID: 8217058]
  • M J Eaton, Y Tian, K J Lookingland, K E Moore. Comparison of the effects of remoxipride and raclopride on nigrostriatal and mesolimbic dopaminergic neuronal activity and on the secretion of prolactin and alpha-melanocyte-stimulating hormone. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 1992 Nov; 7(3):205-11. doi: NULL. [PMID: 1326981]
  • R H Chiou, M W Lo. Determination of remoxipride in human plasma and urine by reversed-phase ion-pair high-performance liquid chromatography. Journal of chromatography. 1992 Oct; 581(2):300-5. doi: 10.1016/0378-4347(92)80287-z. [PMID: 1452624]
  • G A Gudelsky, J F Nash. Neuroendocrinological and neurochemical effects of sigma ligands. Neuropharmacology. 1992 Feb; 31(2):157-62. doi: 10.1016/0028-3908(92)90026-l. [PMID: 1348112]
  • E Ongini, P Bo, S Dionisotti, M Trampus, F Savoldi. Effects of remoxipride, a dopamine D-2 antagonist antipsychotic, on sleep-waking patterns and EEG activity in rats and rabbits. Psychopharmacology. 1992; 107(2-3):236-42. doi: 10.1007/bf02245143. [PMID: 1352054]
  • R L Lahdelma, B Appelberg, K Kuoppasalmi, H Katila, R Rimón. Plasma concentrations of remoxipride and haloperidol in relation to prolactin and short-term therapeutic outcome in schizophrenic patients. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 1991 Dec; 1(4):535-40. doi: 10.1016/0924-977x(91)90007-h. [PMID: 1688013]
  • G Movin-Osswald, M Hammarlund-Udenaes. Remoxipride: pharmacokinetics and effect on plasma prolactin. British journal of clinical pharmacology. 1991 Sep; 32(3):355-60. doi: 10.1111/j.1365-2125.1991.tb03911.x. [PMID: 1685665]
  • C von Bahr, F A Wiesel, G Movin, P Eneroth, P Jansson, L Nilsson, S Ogenstad. Neuroendocrine responses to single oral doses of remoxipride and sulpiride in healthy female and male volunteers. Psychopharmacology. 1991; 103(4):443-8. doi: 10.1007/bf02244242. [PMID: 1676524]
  • E Widerlöv, U Andersson, C von Bahr, M I Nilsson. Pharmacokinetics and effects on prolactin of remoxipride in patients with tardive dyskinesia. Psychopharmacology. 1991; 103(1):46-9. doi: 10.1007/bf02244072. [PMID: 1672458]
  • G H Gu, C K Lim. Separation of anionic and cationic compounds of biomedical interest by high-performance liquid chromatography on porous graphitic carbon. Journal of chromatography. 1990 Aug; 515(?):183-92. doi: 10.1016/s0021-9673(01)89312-2. [PMID: 2178167]
  • E Widerlöv, G Franzén, P Jansson, G Movin. Pharmacokinetics of remoxipride controlled release and immediate release capsules in schizophrenic patients. International clinical psychopharmacology. 1990 Apr; 5(2):125-34. doi: NULL. [PMID: 1974271]
  • L B Nilsson. Determination of remoxipride in plasma and urine by reversed-phase column liquid chromatography. Journal of chromatography. 1990 Mar; 526(1):139-50. doi: 10.1016/s0378-4347(00)82491-3. [PMID: 1971278]
  • T Lewander, S E Westerberg, S O Ogren, C Von Bahr, C Köhler. [Remoxipride, a selective antagonist of dopamine D2 receptors, in the treatment of delusional psychoses]. L'Encephale. 1990 Mar; 16(2):153-7. doi: NULL. [PMID: 1972054]
  • C von Bahr, G Movin, W A Yisak, K G Jostell, M Widman. Clinical pharmacokinetics of remoxipride. Acta psychiatrica Scandinavica. Supplementum. 1990; 358(?):41-4. doi: 10.1111/j.1600-0447.1990.tb05284.x. [PMID: 1978486]
  • W Yisak, C von Bahr, L Farde, M Grind, M Mattila, S Ogenstad. Drug interaction studies with remoxipride. Acta psychiatrica Scandinavica. Supplementum. 1990; 358(?):58-62. doi: 10.1111/j.1600-0447.1990.tb05290.x. [PMID: 1978492]
  • J P Kahn, W Yisak, C Albaret, L Nilsson, A Zaar-Hedin, M Laxenaire. Tolerability and pharmacokinetics of remoxipride after intramuscular administration. Acta psychiatrica Scandinavica. Supplementum. 1990; 358(?):51-3. doi: 10.1111/j.1600-0447.1990.tb05287.x. [PMID: 1978489]
  • J A Den Boer, D P Ravelli, J Huisman, J Ohrvik, W M Verhoeven, H G Westenberg. Double blind comparative study of remoxipride and haloperidol in acute schizophrenic patients. Psychopharmacology. 1990; 102(1):76-84. doi: 10.1007/bf02245748. [PMID: 1975448]
  • D Morrison, A Englund, V Lawrie, T Lewander, A Schlachet, S E Westerbergh. Safety evaluation in both short- and long-term treatment of schizophrenia with remoxipride. Acta psychiatrica Scandinavica. Supplementum. 1990; 358(?):164-9. doi: 10.1111/j.1600-0447.1990.tb05311.x. [PMID: 1978478]
  • S D Soni, D Tench, T J Ashwood, G Movin. Pharmacokinetics of an oral controlled release formulation of remoxipride: a double-blind, crossover comparison with conventional formulation in chronic schizophrenics. Acta psychiatrica Scandinavica. Supplementum. 1990; 358(?):45-7. doi: 10.1111/j.1600-0447.1990.tb05285.x. [PMID: 1978487]
  • K G Jostell, Y D Lapierre. Plasma concentration of remoxipride in relation to antipsychotic effect and adverse symptoms. The Canadian Remoxipride Study Group. Acta psychiatrica Scandinavica. Supplementum. 1990; 358(?):48-50. doi: 10.1111/j.1600-0447.1990.tb05286.x. [PMID: 1978488]
  • C Graffner, Z Wagner, M I Nilsson, E Widerlöv. Plasma concentrations of remoxipride and the gastrointestinal transit of 111In-marked extended-release coated spheres. Pharmaceutical research. 1990 Jan; 7(1):54-8. doi: 10.1023/a:1015835609333. [PMID: 2137217]
  • D Tench, S D Soni, T Ashwood, G Movin. Steady-state pharmacokinetics of controlled release and immediate release formulations of remoxipride in patients with chronic schizophrenia. Psychopharmacology. 1990; 101(1):132-6. doi: 10.1007/bf02253730. [PMID: 1971445]
  • G Sedvall. Monoamines and schizophrenia. Acta psychiatrica Scandinavica. Supplementum. 1990; 358(?):7-13. doi: 10.1111/j.1600-0447.1990.tb05279.x. [PMID: 1978495]
  • R Deo, S Soni, S C Rastogi, S Levine, I Plant, J G Edwards, M Mitchell, A Chanas. Remoxipride and haloperidol in the acute phase of schizophrenia: a double-blind comparison. Acta psychiatrica Scandinavica. Supplementum. 1990; 358(?):120-4. doi: 10.1111/j.1600-0447.1990.tb05302.x. [PMID: 1978470]
  • L Gawell, C E Hagberg, T Högberg, M Widman. Synthesis of 5-substituted 5-hydroxy-2-pyrrolidones, metabolites of the antipsychotic benzamide remoxipride. Acta chemica Scandinavica (Copenhagen, Denmark : 1989). 1989 May; 43(5):476-80. doi: 10.3891/acta.chem.scand.43-0476. [PMID: 2577294]
  • K Andersson. Involvement of D1 dopamine receptors in the control of TSH secretion in the male rat. Acta physiologica Scandinavica. 1989 Apr; 135(4):449-57. doi: 10.1111/j.1748-1716.1989.tb08587.x. [PMID: 2567562]
  • M Segerberg-Konttinen, E Vuori, I Lukkari, A Penttilä. Fatal intoxication by Remoxipride. Journal of forensic sciences. 1989 Mar; 34(2):500-3. doi: NULL. [PMID: 2523466]
  • E Widerlöv, B Termander, M I Nilsson. Effect of urinary pH on the plasma and urinary kinetics of remoxipride in man. European journal of clinical pharmacology. 1989; 37(4):359-63. doi: 10.1007/bf00558500. [PMID: 2574673]
  • M Grind, M I Nilsson, L Nilsson, G Oxenstierna, G Sedvall, A Wahlén. Remoxipride--a new potential antipsychotic compound. Tolerability and pharmacokinetics after single oral and intravenous administration in healthy male volunteers. Psychopharmacology. 1989; 98(3):304-9. doi: 10.1007/bf00451679. [PMID: 2568653]
  • K Andersson, K Fuxe, P Eneroth, A Härfstrand, L F Agnati. Involvement of D1 dopamine receptors in the nicotine-induced neuro-endocrine effects and depletion of diencephalic catecholamine stores in the male rat. Neuroendocrinology. 1988 Aug; 48(2):188-200. doi: 10.1159/000125007. [PMID: 2975769]
  • L Farde, M Grind, M I Nilsson, S Ogenstad, G Sedvall. Remoxipride--a new potential antipsychotic drug. Pharmacological effects and pharmacokinetics following repeated oral administration in male volunteers. Psychopharmacology. 1988; 95(2):157-61. doi: 10.1007/bf00174501. [PMID: 2901121]
  • G Chouinard. Early phase II clinical trial of remoxipride in treatment of schizophrenia with measurements of prolactin and neuroleptic activity. Journal of clinical psychopharmacology. 1987 Jun; 7(3):159-64. doi: NULL. [PMID: 2885345]
  • A C Veltkamp, H A Das, R W Frei, U A Brinkman. On-line low-level radiometric detection of [14C]remoxipride in liquid chromatographic effluents. Application to urine samples. Journal of chromatography. 1987 Jan; 384(?):357-69. doi: 10.1016/s0021-9673(01)94683-7. [PMID: 2880858]
  • J A den Boer, W M Verhoeven, H G Westenberg. Remoxipride in schizophrenia. A preliminary report. Acta psychiatrica Scandinavica. 1986 Oct; 74(4):409-14. doi: 10.1111/j.1600-0447.1986.tb06262.x. [PMID: 2880457]
  • G Chouinard, L Turnier. An early phase II clinical trial of remoxipride in schizophrenia with measurement of plasma neuroleptic activity. Psychopharmacology bulletin. 1986; 22(1):267-71. doi: NULL. [PMID: 2873615]
  • A Lund Laursen, J Gerlach. Antipsychotic effect of remoxipride, a new substituted benzamide with selective antidopaminergic activity. Acta psychiatrica Scandinavica. 1986 Jan; 73(1):17-21. doi: 10.1111/j.1600-0447.1986.tb02659.x. [PMID: 2938421]
  • G Chouinard, L Turnier, M A Kallai-Sanfacon. Remoxipride in schizophrenia: effects on plasma prolactin. Progress in neuro-psychopharmacology & biological psychiatry. 1985; 9(5-6):599-603. doi: 10.1016/0278-5846(85)90024-7. [PMID: 2868493]
  • P E Phillips. The virus hypothesis in systemic lupus erythematosus. Annals of internal medicine. 1975 Nov; 83(5):709-15. doi: 10.7326/0003-4819-83-5-709. [PMID: 938]